How will the Inflation Reduction Act affect life sciences startups, current and future revenues, and drug investment? What will happen to patients amidst the aftermath of unintended consequences? There aren’t too many people who know more about the ins and outs than the fine folks at DLA Piper.
One of the biggest interventions in drug pricing since the Medicare Modernization Act was passed, listen to the inside scoop on what this means for the future of drugs.
Join us as we discuss:
-What drug price negotiations will look like under the act
-How brand competition will play out
-Which drugs and stakeholders will be affected
